# Nephrology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Madam C. J. Walker (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET019-SYN
- Date: 2026-02-23
- Fictional facility: St. Posthumous Health Center
- Fictional author: Desmond Achterberg, MD
- Calendar frame: modern shifted

- Requested by: Harriet Okonjo-Bell, MD

## Reason for consultation

Albumin in the urine (286 mg/g) and an eGFR of 54 by the race-free CKD-EPI 2021 equation in a 49-year-old woman with high blood pressure readings awaiting ambulatory confirmation, left ventricular hypertrophy on ECG and protein on a dipstick a year ago. Please advise on the cause, any further tests, kidney-protective treatment and her blood pressure target, APOL1 testing, and a monitoring plan that fits a schedule of travel most weeks. **S**

## History

Madam Walker, 49, is seen at the request of Dr. Okonjo-Bell on the day of her two-week visit. She asked to be addressed as Madam Walker. Her ambulatory monitor showed a 24-hour mean of 149/94, daytime 154/98 and night 140/88, and her home readings average 152/96. Her office has sent last year's executive physical: creatinine 1.18 mg/dL and protein 1+ on a dipstick. She has had morning headaches on some days. She has no visible blood in the urine, no foamy urine she has noticed, no swelling, rash, joint pain, mouth ulcers or kidney stones, and takes no NSAIDs, supplements or herbal products. No known family kidney disease; both parents died when she was a child. She asked plainly whether she will need dialysis and said she would take whatever medicines were needed but would not give up her travel. **S**

## Examination

| System | Finding |
|---|---|
| General | Well, articulate and engaged |
| Vital signs | Blood pressure 160/100 and pulse 80, measured by the clinic nurse today |
| Cardiovascular | Regular rhythm; sustained apex beat; no bruits |
| Extremities | No ankle swelling; no rash |

BP 160/100 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 78.6 kg; BMI 29.6 kg/m². All vital signs are synthetic.

## Data reviewed

Dr. Okonjo-Bell's intake note and results: creatinine 1.22 mg/dL, eGFR 54 at intake and 1.21 mg/dL, eGFR 55 today (CKD-EPI 2021, race-free); potassium 4.4 mmol/L; urine albumin-to-creatinine ratio 286 mg/g at intake and 294 mg/g today; urinalysis 1+ protein without blood, bland sediment; calcium 9.4 mg/dL, phosphate 3.6 mg/dL, parathyroid hormone 58 pg/mL, 25-hydroxyvitamin D 31 ng/mL; A1c 5.4%; LDL 174 mg/dL; hemoglobin 12.4 g/dL. ECG: left ventricular hypertrophy by voltage. Kidney ultrasound this morning: right kidney 10.4 cm, left 10.6 cm, normal cortical thickness, mildly increased echogenicity, no hydronephrosis, stones or cysts. Ambulatory and home readings as above; clinic 160/100 today. Urine albumin-to-creatinine ratio: 294 mg/g (high); Creatinine: 1.21 mg/dL (high); eGFR (CKD-EPI 2021, race-free): 55 mL/min/1.73 m² (low); Calcium: 9.4 mg/dL; Phosphate: 3.6 mg/dL; Parathyroid hormone (intact): 58 pg/mL; 25-hydroxyvitamin D: 31 ng/mL. All results are synthetic.

## Assessment

1. **Chronic kidney disease G3a A2** (N18.31). Albuminuria and a reduced eGFR present for more than a year: CKD G3a A2, high risk on the KDIGO heat map. Long-standing hypertension with left ventricular hypertrophy and retinopathy, a bland sediment without hematuria, albuminuria below 300 mg/g and normal-sized kidneys make hypertensive kidney disease the most likely cause. A primary glomerular disease is less likely, and a biopsy is not needed now. Her 5-year kidney failure risk is 1.6% (4-variable KFRE): low, and treatment can lower it further. The race-free equation stages her correctly; the older equation with a race coefficient would have reported an eGFR of about 60. **S**
2. **Hypertension with chronic kidney disease** (I12.9). Stage 2 hypertension confirmed by ambulatory monitoring, with a non-dipping pattern. With albuminuria, a renin-angiotensin blocker at the maximum tolerated dose is the foundation, chosen for the kidney disease and not for her race; an ARB avoids the cough of an ACE inhibitor, which matters for her work. Target below 130/80, and a systolic near 120 if she tolerates it with standardized measurement. **S**

## Recommendations

1. Losartan 50 mg each morning, increased to 100 mg after two weeks if potassium is below 5.5 mmol/L and creatinine has risen by less than 30%.
2. Empagliflozin 10 mg daily for kidney protection, indicated at her eGFR and albuminuria without diabetes; expect a small early dip in eGFR.
3. Sick-day rules: hold losartan and empagliflozin on days of vomiting, diarrhea or not eating, and restart after a day of normal eating and drinking.
4. Potassium and creatinine two to four weeks after each start or increase, then every six months with the urine albumin; booking the draws on her days at home is acceptable.
5. Amlodipine as the next medicine if blood pressure stays above goal on the maximum losartan dose; no potassium-based salt substitutes.
6. Hepatitis B, hepatitis C and HIV tests now, as part of the evaluation of new CKD, and hepatitis B vaccination if she is not immune.
7. APOL1 genotyping may be offered with genetic counseling: two high-risk variants raise the lifetime risk of kidney disease and help explain it, but the result would not change today's treatment; it is her choice whether and when to test.
8. No biopsy now; reconsider for hematuria, albuminuria rising above 1,000 mg/g despite treatment, or an unexplained fall in eGFR of more than 30%.
9. Avoid NSAIDs, and tell any clinician about her kidneys before contrast dye.

## Strengths and supports

- Engagement in care and meaningful activity **S**

## Communication

Discussed with Dr. Okonjo-Bell after the visit. The diagnosis, the low 5-year risk and each medicine were explained to Madam Walker with the numbers, and she agreed to start losartan and empagliflozin today. APOL1 testing was explained and written information given; she will decide later. **S**

## Follow-up

Nephrology review in about six months, by video if she prefers, or sooner for potassium above 5.5 mmol/L, a fall in eGFR of more than 30%, albuminuria rising, or blood pressure not at goal on three medicines; Dr. Okonjo-Bell continues care and monitoring. **S**

## Guideline basis

- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (J Am Coll Cardiol 2025)
- KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024), Kidney Disease: Improving Global Outcomes (Kidney International)
- KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021), Kidney Disease: Improving Global Outcomes (Kidney International)
- New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race (2021), Inker LA et al., N Engl J Med 2021
- A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease (2021), National Kidney Foundation and American Society of Nephrology (Am J Kidney Dis 2022)
